

- Coffey, J. T., Brandle, M., Zhou, H., Marriott, D., Burke, R., Tabaei, B. P., & Herman, W. H. (2002). Valuing health-related quality of life in diabetes. *Diabetes care*, 25(12), 2238-2243.
- Collaborative, H. P. S. (2006). Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. *BMJ: British Medical Journal*, 333(7579), 1145.
- Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003). Heart Protection Study. *The Lancet*, 361(9356), 529-530.
- Cowie, M. R. (2005). Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. *International journal of clinical practice*, 59(7), 839-846.
- Crouse III, J. R., Byington, R. P., & Furberg, C. D. (1998). HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. *Atherosclerosis*, 138(1), 11-24.
- Cryer, P. (2002). Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*. *Diabetologia*, 45(7), 937-948.
- Davis, B. R., Cutler, J. A., & Gordon, D. J. (2002). Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). *Jama*, 288(23), 2981-2997.